BioCentury | Feb 21, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers The pre-HIV infection fraction of CD4 + T cells expressing integrin α 4 β 7 could help predict susceptibility to HIV infection. In 70 of 206 at-risk women from South Africa and...
BioCentury | Jun 7, 2017
Distillery Techniques

Drug delivery

...TECHNOLOGY: Other An S. typhimurium -based DNA vaccine vector expressing tumor antigens and Bacterial AIDA-I autotransporter (AIDA-I) could be...
...fusion protein consisting of a tumor antigen recognized by CD4 + T cells linked to AIDA-I...
...1 (TYRP1) and dopachrome tautomerase ( DCT ; TRP-2 ; TYRP2) and a fusion of AIDA-I...
BioCentury | Jun 18, 2015
Distillery Therapeutics

Therapeutics: Interleukin-4 (IL-4; BSF1); IL-4 receptor (CD124; IL-4RA); interleukin-13 (IL-13)

Gastrointestinal disease INDICATION: Pancreatitis In vitro and mouse studies suggest inhibiting IL-4 and IL-13 could help treat chronic pancreatitis. In pancreatic tissues from a mouse model of chronic pancreatitis or from patients with the disease,...
BioCentury | Jan 23, 2014
Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Pancreatitis Toll-like receptor 4 (TLR4) Mouse studies suggest CO-based therapeutics could help treat acute pancreatitis. In two mouse models of acute pancreatitis, a CO-releasing...
BioCentury | Apr 14, 2008
Clinical News

Wetimicin: Phase II start

This year, Aida will begin a Chinese Phase II trial. Aida Pharmaceuticals Inc. (OTCBB: AIDA ), Hangzhou, China Product: Wetimicin Business: Infectious Molecular target: NA Description: Broad spectrum amino-glycoside antibiotic Indication: Treat infections Endpoint: NA...
BioCentury | Mar 31, 2008
Company News

Aida, Jiangsu Institute of Microbiology Co. Ltd. deal

Aida acquired Jiangsu for an undisclosed sum. Aida gets "several" undisclosed compounds that are in clinical trials in China. Aida markets Etimicin sulfate powder and infusion in China to treat inflammatory diseases such as acute...
BioCentury | Jan 15, 2007
Clinical News

Rh-Apo2L: Phase II started

The company began a Chinese Phase II trial in about 100 patients. Aida Pharmaceuticals Inc. (AIDA), Hangzhou, China Product: Rh-Apo2L Business: Cancer Molecular target: Not available Description: Broad spectrum genetic cell apoptosis agent Indication: Treat...
BioCentury | Nov 6, 2006
Clinical News

Rh-Apo2L: Phase III start

By year end, AIDA will begin a Chinese Phase III trial. Aida Pharmaceuticals Inc. ( AIDA ), Hangzhou, China Product: Rh-Apo2L Business: Cancer Molecular target: Not available Description: Broad spectrum genetic cell apoptosis agent Indication: Treat...
BioCentury | Nov 6, 2006
Clinical News

Rh-Apo2L: Phase II start

By year end, AIDA will begin a Chinese Phase II trial. Aida Pharmaceuticals Inc. ( AIDA ), Hangzhou, China Product: Rh-Apo2L Business: Cancer Molecular target: Not available Description: Broad spectrum genetic cell apoptosis agent Indication: Treat...
BioCentury | Aug 21, 2006
Company News

Aida, Shanghai Qiaer Bio-Technology Co. Ltd. deal

AIDA acquired a 33% stake in Qiaer for RMB27.8 million ($3.5 million) and now owns 78% of the company. AIDA Chairman and CEO Jin Biao will be chairman of Qiaer. Qiaer's lead product, Rh-Apo2L gene...
Items per page:
1 - 10 of 13